Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Understanding the kinetics and durability of AAV-mediated transgene expression in the brain is essential for conducting basic neuroscience studies as well as for developing gene therapy approaches for CNS diseases. Here, we characterize and compare the temporal profile of transgene expression after bilateral injections into the mouse striatum of rAAV9 encoding GFP under the control of either a ubiquitous promoter (CAG), or the neuron-specific human synapsin (hSyn) and CamKII promoters. GFP protein expression with the CAG promoter was highest at 3 weeks, and then decreased to stable levels at 3 and 6 months. Surprisingly, GFP mRNA levels continued to increase from 3 weeks to 3 months, despite GFP protein expression decreasing during this time. GFP protein expression with hSyn increased more slowly, reaching a maximum at 3 months, which was equivalent to protein expression levels from CAG at that time point. Importantly, transgene expression driven by the hSyn promoter at 6 months was not silenced as previously reported, and GFP mRNA was continuing to rise even at the final 6-month time point. Thus, hSyn as a promoter for transgene expression demonstrates long-term durability but may require more time after vector administration to achieve steady-state levels. Because CAG had the highest GFP protein expression in our comparison, which was at 3 weeks post administration, the early kinetics of transgene expression from CAG was examined (1, 2, 5, and 10 days after injection). This analysis showed that GFP protein expression and GFP mRNA increased during the first 3 weeks after administration. Interestingly, vector DNA rapidly decreased 10-fold over the first 3 weeks following injection as it assembled into stable circular episomes and concatemers. Surprisingly, the processing of vector genomes into circular episomes and concatemers was continually dynamic up to 3 months after injection. These results provide novel insight into the dynamic processing of vector genomes and promoter-specific temporal patterns of transgene expression in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Cell-type specificity of GFP expression in the striatum of mice. (A) Colocalization of GFP expression with markers of neurons [NeuN] and astrocytes [S100β]. Arrows point out cells with co-localization of GFP with NeuN (white) and S100B (yellow). Percentage of (B) neurons and (C) astrocytes that express GFP in the transduced area. (D) Colocalization of GFP expression with markers of oligodendrocytes (Olig2) and (E) percentage of oligodendrocytes that express GFP in the transduced area. White arrows point out cells with co-localization of GFP with Olig2. (F) Colocalization of GFP expression with markers of microglia (Iba1) and (G) percentage of microglia that express GFP in the transduced area. Scale bar represents 50 μm. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. ***p < 0.001 and #p < 0.0001.](https://figures.cochat.ai/paper-figures/ea533f2a2f9749c2b7e0cc6bb88b77f5/kinetics-and-durability-of-transgene-expression-after-intrastriatal-injection-of-figure-3.jpg)
![Figure 4 Long-term kinetics of rAAV9-CAG-GFP in the striatum in mice. (A) Quantification of luminance from native GFP fluorescence (500 ms exposure) during the first 6 months after rAAV9-CAG-GFP administration. (B) ddPCR analysis measuring the amount of GFP mRNA relative to TBP mRNA and (C) GFP DNA copies per cell as determined by copy numbers of GFP to two glucagon copies per cell during the first 6 months after administration of rAAV9-CAG-GFP. Data from 3 weeks, 3 and 6 months was previously presented in Figure 2. (D) The number of circular DNA units that contain an AAV genome (not considering concatemers) per cell, (E) the total number of AAV genomes in circular DNA per cell (diploid genome) and (F) the average number of AAV genomes per circular episome [values from (E) divided by values from (D)] in the striatum of mice during the first 6 months after administration of rAAV9-CAG-GFP. Data was analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001. Significance symbols in parentheses are compare with day 1.](https://figures.cochat.ai/paper-figures/9d79debaa3c841fca1902391d9c669eb/kinetics-and-durability-of-transgene-expression-after-intrastriatal-injection-of-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This vector dose was chosen as a standard dose used for pre-clinical testing in several settings, independently of toxicity, and because it has been shown to induce glial cell activation and brain infiltration in previous mouse studies using the same route of administration 36,37,100 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578 · cited 12×
“In the CNS, the neuron-specific promoters, hSyn and CamKII, have been shown to drive reliable and robust expression that restricts primarily to neurons (18– 20).”
BackgroundInfluentialEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 2×
“Once the single-stranded, linear vector DNA is transported to the nucleus, second strand synthesis occurs resulting in double-stranded, linear genomes (1).”
BackgroundHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · cited 1×
“Such large doses increase immune responses to the vector and can lead to hepatotoxicity as well as complement activation (7, 8).”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420 · cited 3×
“GFP mRNA expression was also found to significantly change over the course of time depending on the promoter [Figure 2C; two-way ANOVA, F(4,26) (time × promoter) = 25.”
BackgroundMethodPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Research works printed but not linked: 1
- Batty, 2020, Frequency, location and nature of AAV vector insertions after long-term follow up of FVIII transgene delivery in a hemophilia A dog model [abstract], Res. Pract. Thromb. Haemost., 4, 550
Cited by
Zwang, T. J., Sastre, E. D., Wolf, N., Ruiz-Uribe, N., Woost, B., Hoglund, Z., Fan, Z., Bailey, J., Nfor, L., Buée, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114574 · Cited by 48
“Prior studies have evaluated the tropism of these capsids for neurons and report that this is an effective system for delivering genes broadly to excitatory neurons 27–29 ; however, this method may not have captured the full spectrum of disease-susceptible neurons.”
BackgroundCosta-Verdera, H., Meneghini, V., Fitzpatrick, Z., Abou Alezz, M., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58778-3 · Cited by 32
“…with AAV9-CAG-GFP or vehicle ( n = 2 mice/group respectively) andweresacri fi ced28 dayspost-injection, atime-point at which robust transgene expression can be expected 35,36 and CNS toxicities havebeenreported 11,15,37 ,whichintheDRGcontexthavebeenshownto be transgene expression-dependent 38 .”
AAV vectors trigger DNA damage responses and STING-dependent inflammation in human CNS cells
Costa-Verdera, H., Meneghini, V., Fitzpatrick, Z., Alezz, M. A., Fabyanic, E., Huang, X., Dzhashiashvili, Y., Ahiya, A., Mangiameli, E., Valeri, E., et al. (2024) · doi:10.21203/rs.3.rs-4171795/v1 · Cited by 32
Feng, X., Jiang, B., Zhai, S.-N., Liu, C., Wu, H., Zhu, B.-Q., Wei, M.-Y., Wei, J., Yang, L. C., & Chen, L. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02624-w · Cited by 48
“3c), consistent with the previous report 40 .”
Mora, J. R., Palmer, R., Wagner, L., Wu, B., Partridge, M. A. K., Meena, Sonderegger, I., Smeraglia, J., Bivi, N., Dakappagari, N. K., et al. (2024) · Bioanalysis · doi:10.4155/bio-2024-0024 · Cited by 22
Metadata
- Authors
- Hollidge, B. S., Carroll, H. B., Qian, R., Fuller, M. L., Giles, A. R., Mercer, A. C., Danos, O., Liu, Y., Bruder, J. T., & Smith, J. B.
- Affiliations
- Regenxbio (United States) (US)
- Corresponding author
- Smith, Jared B.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-14
- Volume
- 13
- Pages
- 1051559-1051559
- ISSN
- 1664-2295 (ISSN-L)
- PMC
- PMC9702554
- OpenAlex
- W4309012465
- Cited by
- 45
- References
- 27
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 6 · 2023: 4
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- REGENXBIO
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- AAV9, adeno-associated virus vectors, intrastriatal injection, transgene expression kinetics, striatum, synapsin promoter, CAG promoter, green fluorescent protein, episomes, concatemers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. https://app.cochat.ai/papers/10.3389/fneur.2022.1051559
- The paper
- Hollidge, B. S., Carroll, H. B., Qian, R., Fuller, M. L., Giles, A. R., Mercer, A. C., Danos, O., Liu, Y., Bruder, J. T., & Smith, J. B. (2022). Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors. Frontiers in Neurology. https://doi.org/10.3389/fneur.2022.1051559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.